Analyst Price Targets — TXG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 2, 2026 1:18 pm | Daniel Arias | Stifel Nicolaus | $25.00 | $22.38 | StreetInsider | 10X Genomics (TXG) PT Raised to $25 at Stifel on Solid New Product Adoption |
| February 20, 2026 11:39 am | — | UBS | $20.00 | $19.19 | TheFly | 10x Genomics price target raised to $20 from $14 at UBS |
| February 13, 2026 1:36 pm | — | Deutsche Bank | $17.00 | $19.40 | TheFly | 10x Genomics price target raised to $17 from $16 at Deutsche Bank |
| February 13, 2026 12:08 pm | — | Stifel Nicolaus | $20.00 | $17.51 | TheFly | 10x Genomics price target raised to $20 from $15 at Stifel |
| February 13, 2026 12:05 pm | Kyle Mikson | Canaccord Genuity | $22.00 | $17.51 | TheFly | 10x Genomics price target raised to $22 from $20 at Canaccord |
| January 12, 2026 9:20 am | — | Needham | $21.00 | $20.46 | StreetInsider | 10X Genomics (TXG) PT Raised to $21 at BofA Securities |
| December 22, 2025 12:02 pm | — | Canaccord Genuity | $20.00 | $16.05 | TheFly | 10x Genomics price target raised to $20 from $19 at Canaccord |
| December 15, 2025 10:54 am | — | Barclays | $22.00 | $15.45 | TheFly | 10x Genomics price target raised to $22 from $17 at Barclays |
| December 1, 2025 9:21 pm | Kallum Titchmarsh | Morgan Stanley | $20.00 | $18.08 | TheFly | 10x Genomics assumed at Equal Weight from Overweight at Morgan Stanley |
| August 11, 2025 12:43 pm | Kyle Mikson | Canaccord Genuity | $16.00 | $12.39 | TheFly | 10x Genomics price target raised to $16 from $15 at Canaccord |
Latest News for TXG
Decision Diagnostics (OTCMKTS:DECN - Get Free Report) and 10x Genomics (NASDAQ: TXG - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings. Profitability This table compares Decision Diagnostics and 10x
Biotricity (OTCMKTS:BTCY - Get Free Report) and 10x Genomics (NASDAQ: TXG - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Valuation and Earnings This table compares Biotricity and 10x
PLEASANTON, Calif., Feb. 19, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, at 11:50 a.m.
Torex Gold Resources Inc. (TXG:CA) Q4 2025 Earnings Call Transcript
10x Genomics, Inc. (TXG) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TXG.
U.S. House Trading
No House trades found for TXG.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.